Quantcast
Home > Quotes > ALIM

Alimera Sciences, Inc. Common Stock (ALIM) Quote & Summary Data

ALIM 
$1.145
*  
0.105
10.1%
Get ALIM Alerts
*Delayed - data as of Jul. 18, 2018  -  Find a broker to begin trading ALIM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.165 / $ 1.03
Share Volume
128,631
50 Day Avg. Daily Volume
169,169
Previous Close
$ 1.04
52 Week High / Low
$ 1.65 / $ 0.74
Market Cap
80,193,981
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
128,631
50 Day Avg. Daily Volume:
169,169

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.33

Trading Range

The current last sale of $1.145 is 54.73% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.165 $ 1.65
 Low: $ 1.03 $ 0.74

Company Description (as filed with the SEC)

Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We presently focus on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and represent a significant market opportunity. Our only commercial product is ILUVIENĀ®, which was initially developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom.  ... More ...  

Risk Grade

Where does ALIM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.04
Open Date:
Jul. 18, 2018
Close Price:
$ 1.145
Close Date:
Jul. 18, 2018

Consensus Recommendation

Analyst Info